AbbVie Inc. $ABBV Shares Sold by Lockheed Martin Investment Management Co.

Lockheed Martin Investment Management Co. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 43.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,310 shares of the company’s stock after selling 30,390 shares during the period. Lockheed Martin Investment Management Co.’s holdings in AbbVie were worth $9,333,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Conning Inc. increased its position in shares of AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after acquiring an additional 12,690 shares in the last quarter. Diversified Trust Co raised its stake in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares during the period. Dohj LLC raised its stake in AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares during the period. Permanent Capital Management LP purchased a new stake in shares of AbbVie in the third quarter valued at $720,000. Finally, Railway Pension Investments Ltd boosted its position in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after buying an additional 211,800 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $218.05 on Friday. The company has a market capitalization of $385.38 billion, a P/E ratio of 165.19, a P/E/G ratio of 0.88 and a beta of 0.36. The stock’s 50 day moving average price is $225.87 and its 200 day moving average price is $216.99. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the company earned $3.00 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is 524.24%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ABBV shares. Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Bank of America lifted their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research report on Thursday, January 15th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.